Two Sigma Investments LP Cuts Position in Sensus Healthcare, Inc. (NASDAQ:SRTS)

Two Sigma Investments LP cut its position in Sensus Healthcare, Inc. (NASDAQ:SRTS - Free Report) by 41.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 90,523 shares of the company's stock after selling 63,521 shares during the quarter. Two Sigma Investments LP owned about 0.55% of Sensus Healthcare worth $626,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of the company. Man Group plc raised its position in Sensus Healthcare by 34.0% in the 4th quarter. Man Group plc now owns 59,338 shares of the company's stock worth $411,000 after purchasing an additional 15,059 shares during the period. OMERS ADMINISTRATION Corp purchased a new position in Sensus Healthcare in the 4th quarter worth $381,000. Millennium Management LLC raised its position in Sensus Healthcare by 256.6% in the 4th quarter. Millennium Management LLC now owns 85,329 shares of the company's stock worth $590,000 after purchasing an additional 61,403 shares during the period. BNP Paribas Financial Markets purchased a new position in Sensus Healthcare in the 4th quarter worth $47,000. Finally, Jane Street Group LLC raised its position in Sensus Healthcare by 233.7% in the 4th quarter. Jane Street Group LLC now owns 47,623 shares of the company's stock worth $330,000 after purchasing an additional 33,353 shares during the period. 25.30% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have issued reports on SRTS. Maxim Group decreased their price objective on shares of Sensus Healthcare from $14.00 to $10.00 and set a "buy" rating on the stock in a research report on Monday, May 19th. HC Wainwright restated a "buy" rating and issued a $12.00 price objective on shares of Sensus Healthcare in a research report on Friday, April 4th. Lake Street Capital decreased their price objective on shares of Sensus Healthcare from $18.00 to $13.00 and set a "buy" rating on the stock in a research report on Tuesday, March 11th. Finally, Wall Street Zen cut shares of Sensus Healthcare from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. One analyst has rated the stock with a sell rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $11.67.

Sensus Healthcare Stock Performance

Shares of NASDAQ SRTS traded down $0.03 during midday trading on Wednesday, hitting $5.10. 82,437 shares of the company traded hands, compared to its average volume of 198,011. Sensus Healthcare, Inc. has a 12-month low of $4.01 and a 12-month high of $9.33. The stock has a 50-day moving average price of $4.63 and a 200 day moving average price of $5.82. The firm has a market cap of $83.87 million, a P/E ratio of 12.75 and a beta of 1.32.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last announced its quarterly earnings results on Thursday, May 15th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.20). Sensus Healthcare had a net margin of 15.90% and a return on equity of 12.60%. The company had revenue of $8.34 million for the quarter, compared to analysts' expectations of $7.23 million. As a group, equities analysts expect that Sensus Healthcare, Inc. will post 0.32 earnings per share for the current year.

Sensus Healthcare Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.